Rare diseases research and practice

Endocrine Development

Volumn 27, Issue , 2014, Pages 234-256

  Polizzi, Agata ^a   Balsamo, Antonio ^b,c   Bal, Milva Orquidea ^b   Taruscio, Domenica ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ARTICLE; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPLETE ANDROGEN INSENSITIVITY SYNDROME; CONGENITAL ADRENAL HYPERPLASIA; DIAGNOSTIC ACCURACY; DISEASE REGISTRY; DISORDER OF SEX DEVELOPMENT; EARLY INTERVENTION; EUROPE; FAMILY; GENE SEQUENCE; GENETIC ASSOCIATION; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; PATIENT EDUCATION; PHENOTYPE; PLASTIC SURGERY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RARE DISEASE; RISK REDUCTION; UNITED STATES; RESEARCH;

DISORDERS OF SEX DEVELOPMENT; HUMANS; RARE DISEASES; RESEARCH;

EID: 84925719013     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000363670     Document Type: Article

References (49)

1. Eur-Lex: Access to European Union law. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. http://eur-lex.europa.eu.
2. European Commission: Programme of community action on rare diseases (1999-2003). Decision No. 1295/99/EC of the European Parliament and of the Council of 29 April 1999. http://ec.europa.eu/health/archive/ph-overview/previous-programme/rare-diseases/raredis-wpgm99-en.pdf.
3. Orphanet Report Series, Rare Diseases Collection: Prevalence of rare diseases: Bibliographic data. Listed in alphabetical order of disease or group of diseases. May 2014, number 1. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence-of-rare-diseases-by-alphabetical-list.pdf.
4. Commission of the European Communities: Commission communication on the framework for action in the field of public health. Brussels, November 1993. http://aei.pitt.edu/5792/1/5792.pdf.
5. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe's challenges. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:52008DC0679:EN:NOT.
6. Council of the European Union: Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Off J Eur Union 2009;C151: 7-10. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF.
7. European Parliament and the Council of the European Union: Directives. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients' rights in crossborder healthcare. Off J Eur Union 2011;L88: 45-65. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF.
8. EUCERD: European Union Committee of Experts on Rare Diseases. http://www.eucerd.eu.
9. EUCERD: Joint Action Working for Rare Diseases (No. 2011 22 01). http://www.eucerd.eu/?page-id=54.
10. EUCERD: 2013 report on the state of the art of rare disease activities in Europe. Part 1: overview of rare disease activities in Europe. http://www.eucerd.eu/upload/file/Reports/2013ReportStateofArtRDActivities.pdf.
11. Commission Expert Group on Rare Diseases: European Commission Decision 2013/C 219/04. http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=3015.
12. Taruscio D, Vittozzi L, Stefanov R: National plans and strategies on rare diseases in Europe. Adv Exp Med Biol 2010; 686: 475-491.
13. Forman J, Taruscio D, Llera VA, Barrera LA, Cotè TR, Edfiall C, Gavhed D, Haffner ME, Nishimura Y, Posada M, Tambuyzer E, Groft SC, Henter Jl, International Conference for Rare Diseases and Orphan Drugs (ICORD): The need for worldwide policy and action plans for rare diseases. Acta Pediatr 2012; 101: 805-807.
14. Taruscio D, Gentile AE, De Santis M, Ferrelli RM, Posada de la Paz M, Hens M, Huizer J, Fregonese L, Stefanov R, Bottarelli V, Weinman A, Le Cam Y, Gavhed D, Mincarone P, Bushby K, Frazzica RG, Donati C, Vittozzi L, Jessop E: EUROPLAN: a project to support the development of national plans on rare diseases in Europe. Public Health Genomics 2013; 16: 278-287.
15. EUROPLAN: European Project for Rare Diseases National Plans Development. http://www.europlanproject.eu.
16. EUCERD: 2009 report on initiatives and incentives in the field of rare diseases of the European Union Committee of Expert on Rare Diseases. http://www.eucerd.eu/?post-type=document&p=1365.
17. EUROPLAN: Recommendations for the development of national plans for rare diseases: guidance document. http://www.europlanproject.eu/-newsite-986989/Resources/docs/2008-2011-2.EuroplanRecommendations.pdf.
18. EUROPLAN: Selecting indicators to evaluate the achievements of RD initiatives. http://www.europlanproject.eu/-newsite-986989/Resources/docs/2008-2011-3.EuroplanIndicators.pdf.
19. EUROPLAN, EURORDIS: Main results of the 15 EUROPLAN national conferences: final report. http://www.europlanproject.eu/-newsite-986989/Resources/docs/2008-2011-4.EuroplanFINALREPORT.pdf.
20. EUCERD: Recommendations on core indicators for rare disease national plans/strategies. June 6, 2013. http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD-Recommendations-Indicators-adopted.pdf.
21. European Medicines Agency: Medicines for Rare diseases. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special-topics/general/general-content-000034.jsp&mid=WC0b01ac058002d4eb.
22. Weber GM: Identifying translational science within the triangle of biomedicine. J Transl Med 2013; 24: 126.
23. NIH Office of History: Rare diseases act 2002. http://history.nih.gov/research/downloads/PL107-280.pdf.
24. Groft SC, Rubinstein YR: New and evolving rare diseases research programs at the National Institutes of Health. Public Health Genomics 2013; 16: 259-267.
25. E-Rare: ERA-Net for research programmes on rare diseases. http://www.erare.eu.
26. IRDiRC: International Rare Diseases Research Consortium. http://www.irdirc.org.
27. Taruscio D, Arriola L, Baldi F, Barisic I, Bermejo-Sánchez E, Bianchi F, Calzolari E, Carbone P, Curran R, Garne E, Gatt M, Latos-Bielenska A, Khoshnood B, Irgens L, Mantovani A, Martínez-Frías ML, Neville A, Rissmann A, Ruggeri S, Wellesley D, Dolk H: European recommendations for primary prevention of congenital anomalies: a joined effort of EUROCAT and EUROPLAN projects to facilitate inclusion of this topic in the national rare disease plans. Public Health Genomics 2014, DOI: 10.1159/000362945.
28. Rare Diseases Task Force Report: Overview of current centres of reference on rare diseases in the EU. September 2005. http://www.eucerd.eu/upload/file/Publication/RDTFECR2005.pdf.
29. Rare Diseases Task Force: Centres of reference for rare diseases in Europe: state of the art in 2006 and recommendations of the Rare Diseases Task Force. http://ec.europa.eu/health/archive/ph-threats/non-com/docs/contribution-policy.pdf.
30. EUCERD: Quality criteria for centres of expertise for rare diseases in member states. October 24, 2011. http://www.eucerd.eu/?post-type=document&p=1224.
31. EUCERD: Recommendations on rare disease European reference networks (RD ERNS). January 31, 2013. http://www.eucerd.eu/?post-type=document& p=2207.
32. European Commission: Commission delegated decision of 10.3.2014 setting out criteria and conditions that European Reference Networks and healthcare providers wishing to join a European Reference Network must fulfil. Brussels, 2014. http://ec.europa.eu/transparency/regdoc/rep/3/2014/EN/3-2014-1408-EN-F1-1.Pdf.
33. Hughes IA, Houk C, Ahmed SF, Lee PA, LWPES Consensus Group, ESPE Consensus Group: Consensus statement on management of intersex disorders. Arch Dis Child 2006; 91: 554-563.
34. Lajic S, Nordenstrom A, Martin Ritzen E, Wedell A: Prenatal treatment of congenital adrenal hyperplasia European. Eur J Endocrinol 2004; 151:U63-U69.
35. Hirvikoski T, Nordenström A, Wedell A, Ritzén M, Lajic S: Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience and standpoint. J Clin Endocrinol Metab 2012; 97: 1881-1883.
36. Auchus RJ, Witchel SF, Leight KR, et al: Guidelines for the development of comprehensive care centers for congenital adrenal hyperplasia: guidance from the CARES Foundation Initiative. Int J Pediatr Endocrinol 2010; 2010: 27521.
37. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr: Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85: 1114-1120.
38. Harbison MD, Lin-Su K, New MI: Growth hormone treatment in children with congenital adrenal hyperplasia. Adv Exp Med Biol 2011; 707: 107.
39. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Analogs Consensus Conference Group: Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752-e762.
40. Whitaker MJ, Debono M, Huatan H, Merke DP, Arlt W, Ross RJ: An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol 2014; 80: 554-561.
41. Hiort O, Wunsch L, Cools M, Looijenga L, Cuckow P: Requirements for a multicentric multidisciplinary registry on patients with disorders of sex development. J Pediatr Urol 2012; 8: 624-628.
42. Ahmed SF, Rodie M, Jiang J, Sinnott RO: The European disorder of sex development registry: a virtual research environment. Sex Dev 2010; 4: 192-198.
43. Newborn screening: toward a uniform screening panel and system. Genet Med 2006; 8(suppl 1):1S- 252S.
44. Scala I, Parenti G, Andria G: Universal screening for inherited metabolic diseases in the neonate (and the fetus). J Matern Fetal Neonatal Med 2012; 25( suppl 5):4-6.
45. Balsamo A, Baldazzi L, Menabò S, Cicognani A: Impact of molecular genetics on congenital adrenal hyperplasia management. Sex Dev 2010; 4: 233-248.
46. Howell RR: Letter to Michael Leavitt, Secretary, US Department of Health and Human Services. http://www.hrsa.gov/heritabledisorderscommittee/correspondence/sep2005letter.htm.
47. Maschke KJ: Disputes over research with residual newborn screening blood specimens. Bioethics Forum, Hastings Center Report, 2009. http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=3826.
48. Ahmed SF, Achermann J, Arlt W, Balen AH, Conway G, Edwards ZL, Elford S, Hughes IA, Izatt L, Krone N, Miles HL, O'Toole S, Les Perry, Sanders C, Simmonds M, Wallace AM, Watt A, Willis D: UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development. Clin Endocrinol 2011; 75: 12-26.
49. Cull ML, Simmonds M: Importance of support groups for intersex (disorders of sex development) patients, families and the medical profession. Sex Dev 2010; 4: 310-312.